Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae

We have identified recombinant human cystatins 9 (rCST9) and C (rCSTC) as a combination immunotherapeutic treatment against multidrug-resistant (MDR) New Delhi metallo-β-lactamase-1 (NDM-1)-producing Klebsiella pneumoniae. We evaluated the lasting protection of rCST9/rCSTC treatment against MDR NDM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Holloway, Alex J., Yu, JiehJuen, Arulanandam, Bernard P., Milligan, Gregg N., Eaves-Pyles, Tonyia D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496045/
https://www.ncbi.nlm.nih.gov/pubmed/30782995
http://dx.doi.org/10.1128/AAC.02519-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496045/
https://www.ncbi.nlm.nih.gov/pubmed/30782995
http://dx.doi.org/10.1128/AAC.02519-18

Ejemplares similares